Another research in melanoma patients found that different apoE isoform allele carriers had significantly different tumour immunological biology and clinical outcomes, which was the first to give evidence that pre-existing genes in the genome can influence malignancy progression and patients’ prognosis (Ostendorf et al. 2020). The gene discussed is APOE; the disease is melanoma.